Clinical Approach to Dysarthria

Comprehensive Practical Framework

1
Symptom Overview
Overview
2
Pathophysiology
Mechanism
3
History Taking
History
4
Physical Examination
Examination
5
Differential Diagnosis
Differential
6
Investigations
Workup
7
Clinical Decision-Making
Algorithm
8
Pearls and Pitfalls
Summary

1. Symptom Overview

Understanding the clinical significance and classification of dysarthria

Dysarthria is one of the most common speech disorders encountered in neurological practice, affecting approximately 170 per 100,000 adults in the general population. Among patients with neurological disease, prevalence is substantially higher: up to 90% of patients with amyotrophic lateral sclerosis, 70-90% of patients with Parkinson disease, and 20-30% of stroke survivors experience dysarthria. This motor speech disorder significantly impacts communication, quality of life, and can serve as a critical localizing sign pointing toward the underlying neurological pathology.

Definition

Dysarthria is a motor speech disorder resulting from neurological impairment affecting the motor control of the speech mechanism. It involves weakness, slowness, or incoordination of the muscles used for speech production, including those controlling respiration, phonation, resonance, articulation, and prosody. Unlike aphasia, language comprehension and formulation remain intact — the deficit lies in the mechanical execution of speech.

Critical Distinction: Dysarthria vs Aphasia vs Apraxia of Speech

Dysarthria

Motor execution problem
Consistent errors
Affects all speech tasks equally
Often affects non-speech oral movements

Aphasia

Language problem
Word-finding difficulty
May affect comprehension
Writing often impaired

Apraxia of Speech

Motor planning problem
Inconsistent, groping errors
Worse with volitional speech
Non-speech movements intact

Classification by Duration and Onset

Category	Onset/Duration	Common Causes	Clinical Significance
Acute	Minutes to hours	Stroke, traumatic brain injury, drug intoxication, hypoglycemia	Medical emergency — requires immediate evaluation for stroke or other acute pathology
Subacute	Days to weeks	Guillain-Barré syndrome, myasthenia gravis crisis, encephalitis, brain tumor	Suggests progressive or inflammatory process; warrants urgent workup
Chronic Progressive	Months to years, worsening	Parkinson disease, amyotrophic lateral sclerosis, multiple sclerosis, progressive supranuclear palsy	Indicates neurodegenerative or demyelinating disease; pattern helps localize pathology
Chronic Stable	Months to years, stable	Prior stroke, prior traumatic brain injury, cerebral palsy	Residual deficit from prior insult; focus on rehabilitation

Classification by Dysarthria Type

The Mayo Clinic classification system identifies six primary types of dysarthria based on perceptual speech characteristics. Each type correlates with specific neuroanatomical localization and underlying pathology.

Type	Lesion Location	Speech Characteristics	Associated Conditions
Flaccid	Lower motor neuron (cranial nerves, neuromuscular junction, muscle)	Breathy voice, hypernasality, imprecise consonants, short phrases	Myasthenia gravis, Guillain-Barré syndrome, bulbar amyotrophic lateral sclerosis, brainstem stroke
Spastic	Bilateral upper motor neuron (corticobulbar tracts)	Strained-strangled voice, slow rate, imprecise consonants, hypernasality	Bilateral stroke, primary lateral sclerosis, cerebral palsy
Ataxic	Cerebellum or cerebellar pathways	Scanning speech, irregular articulatory breakdowns, excess and equal stress	Cerebellar stroke, multiple sclerosis, spinocerebellar ataxia, alcohol intoxication
Hypokinetic	Basal ganglia (substantia nigra)	Monopitch, monoloudness, reduced stress, rapid rate with rushes, soft voice	Parkinson disease, progressive supranuclear palsy, drug-induced parkinsonism
Hyperkinetic	Basal ganglia (various circuits)	Variable depending on movement disorder: voice arrests, strained voice, irregular articulatory breakdowns	Huntington disease, dystonia, essential tremor, tardive dyskinesia
Mixed	Multiple motor systems	Combination of features from multiple types	Amyotrophic lateral sclerosis (flaccid-spastic), multiple sclerosis, Wilson disease, traumatic brain injury

Classification by Temporal Pattern

Pattern	Description	Suggests
Constant	Speech consistently impaired regardless of time of day or fatigue	Structural lesion: stroke, tumor, degenerative disease
Fluctuating	Worse with fatigue, better after rest; varies throughout day	Myasthenia gravis — highly specific pattern
Episodic	Normal speech punctuated by episodes of dysarthria	Transient ischemic attack, multiple sclerosis relapse, metabolic disturbance
Progressive	Gradual worsening over weeks to months	Neurodegenerative disease, expanding mass lesion
Medication-related	Correlates with medication timing (improvement or worsening)	Parkinson disease “wearing off,” medication toxicity

Classification by Severity

Mild Dysarthria

Speech is intelligible but noticeably different. Listener may need occasional clarification. Patient can communicate effectively in most situations. Often described as sounding “different” or having a “thick tongue.”

Moderate Dysarthria

Speech is frequently difficult to understand. Listener requires significant effort and context clues. Patient may need to repeat frequently. Communication is possible but impaired.

Severe Dysarthria

Speech is largely unintelligible. Only occasional words or phrases understood. Patient relies heavily on context, gestures, or augmentative communication. Significant functional limitation.

Anarthria

Complete inability to produce intelligible speech despite intact language function. Patient requires alternative communication methods. Seen in severe bulbar disease or bilateral motor pathway damage.

Key Concept: Dysarthria Type = Neuroanatomical Localization

The pattern of speech abnormality directly reflects the location of neurological damage. Recognizing dysarthria type allows you to localize the lesion before imaging:

Flaccid → Lower motor neuron or neuromuscular junction
Spastic → Bilateral upper motor neuron (corticobulbar)
Ataxic → Cerebellum or cerebellar connections
Hypokinetic → Basal ganglia (dopaminergic pathways)
Hyperkinetic → Basal ganglia (various circuits)
Mixed → Multiple motor systems (e.g., amyotrophic lateral sclerosis affects both upper and lower motor neurons)

Impact on Quality of Life

Beyond the Neurological Deficit

Dysarthria significantly impacts patients beyond communication difficulty:

Social isolation: Patients may withdraw from conversation due to embarrassment or frustration
Depression and anxiety: Common comorbidities, especially in progressive conditions
Employment: May affect occupational function, particularly in communication-dependent roles
Safety concerns: Difficulty calling for help in emergencies
Caregiver burden: Family members may struggle with communication

Always assess the functional and psychosocial impact, not just the neurological deficit.

2. Pathophysiology and Mechanisms

Understanding the neural control of speech and how lesions produce dysarthria

Speech production is one of the most complex motor tasks performed by humans, requiring precise coordination of over 100 muscles across respiratory, laryngeal, velopharyngeal, and articulatory systems. Understanding the neural pathways controlling speech is essential for localizing lesions and interpreting dysarthria patterns.

The Five Subsystems of Speech Production

Subsystem	Structures Involved	Function	Impairment Manifestation
Respiration	Diaphragm, intercostal muscles, abdominal muscles	Provides airflow and subglottic pressure for phonation	Short phrases, reduced loudness, breath support problems
Phonation	Larynx, vocal folds	Vibration of vocal folds produces voice	Breathy, harsh, or strained voice quality; pitch abnormalities
Resonance	Velum (soft palate), pharynx, nasal cavity	Modifies sound quality; velopharyngeal valve separates oral and nasal cavities	Hypernasality, nasal emission, hyponasality
Articulation	Tongue, lips, jaw, teeth	Shapes airflow into recognizable speech sounds	Imprecise consonants, distorted vowels, slurred speech
Prosody	Integration of all systems under cortical and subcortical control	Rhythm, stress, intonation patterns that convey meaning and emotion	Monopitch, monoloudness, inappropriate stress patterns, scanning speech

Neural Control of Speech: The Motor Pathway

Level	Structure	Function	Dysarthria Type if Damaged
Planning and Programming	Left inferior frontal gyrus (Broca’s area), supplementary motor area, premotor cortex	Motor planning and sequencing of speech movements	Apraxia of speech (not true dysarthria)
Upper Motor Neuron	Primary motor cortex → Corticobulbar tracts	Initiates voluntary movement; descends to brainstem nuclei	Spastic (requires bilateral damage due to bilateral innervation)
Cerebellar Circuit	Cerebellum, cerebellar peduncles	Coordinates timing, force, and direction of movements	Ataxic
Basal Ganglia Circuit	Caudate, putamen, globus pallidus, substantia nigra, subthalamic nucleus	Regulates movement amplitude, speed, and initiation; modulates cortical output	Hypokinetic or Hyperkinetic
Lower Motor Neuron	Cranial nerve nuclei (V, VII, IX, X, XII) and their peripheral nerves	Final common pathway; directly innervates speech muscles	Flaccid
Neuromuscular Junction	Motor end plates on speech muscles	Transmits neural signal to muscle	Flaccid (fatigable pattern)
Muscle	Respiratory, laryngeal, velopharyngeal, lingual, labial muscles	Executes speech movements	Flaccid (myopathic pattern)

Cranial Nerves Essential for Speech

Trigeminal Nerve (CN V)

Motor function: Muscles of mastication (jaw movement)

Speech role: Jaw opening and closing for articulation

If damaged: Jaw deviation, imprecise articulation of bilabials and linguadentals

Facial Nerve (CN VII)

Motor function: Muscles of facial expression

Speech role: Lip movement for bilabial sounds (p, b, m) and labiodental sounds (f, v)

If damaged: Imprecise bilabials, drooling, asymmetric smile

Glossopharyngeal Nerve (CN IX)

Motor function: Stylopharyngeus muscle

Speech role: Contributes to pharyngeal movement and swallowing

If damaged: Rarely isolated; contributes to resonance problems

Vagus Nerve (CN X)

Motor function: Laryngeal muscles (via recurrent and superior laryngeal branches), velum, pharynx

Speech role: Phonation, velopharyngeal closure

If damaged: Breathy/hoarse voice, hypernasality, vocal fold paralysis

Accessory Nerve (CN XI)

Motor function: Sternocleidomastoid, trapezius (cranial portion contributes to vagus)

Speech role: Head positioning; some contribution to respiratory support

If damaged: Minimal direct speech impact

Hypoglossal Nerve (CN XII)

Motor function: Intrinsic and extrinsic tongue muscles

Speech role: Critical for all lingual sounds (most consonants and vowels)

If damaged: Imprecise consonants, tongue deviation, atrophy, fasciculations

Pathophysiological Mechanisms by Dysarthria Type

Dysarthria Type	Pathophysiology	Why Speech Sounds This Way	Associated Physical Findings
Flaccid	Lower motor neuron damage → denervation → muscle weakness, hypotonia, atrophy	Weak muscles cannot generate adequate force or sustain contraction; air escapes through incompetent velopharyngeal valve	Fasciculations, atrophy, hyporeflexia, hypotonia
Spastic	Bilateral upper motor neuron damage → loss of inhibition → increased tone, slow movement, weakness	Hypertonicity restricts range and speed of movement; strained quality from effortful forcing through spastic muscles	Hyperreflexia, spasticity, pseudobulbar affect, pathological reflexes
Ataxic	Cerebellar or cerebellar pathway damage → loss of coordination, timing errors	Inability to coordinate force, timing, and direction produces irregular breakdowns; overshooting and undershooting targets	Limb ataxia, intention tremor, dysdiadochokinesia, gait ataxia, nystagmus
Hypokinetic	Dopamine depletion in basal ganglia → reduced movement amplitude and initiation	Movements are reduced in size (hypophonia) and speed; rigidity limits range; festination in speech mirrors gait	Bradykinesia, rigidity, rest tremor, masked facies, shuffling gait
Hyperkinetic	Basal ganglia dysfunction → involuntary movements superimposed on voluntary speech	Involuntary movements (chorea, dystonia, tremor, tics) interrupt smooth speech production	Chorea, dystonia, tremor, athetosis, myoclonus, tics
Mixed (Flaccid-Spastic)	Combined upper and lower motor neuron damage (as in amyotrophic lateral sclerosis)	Features of both: weakness with atrophy plus spasticity with slow, effortful speech	Both upper motor neuron signs (hyperreflexia) and lower motor neuron signs (atrophy, fasciculations)

Key Concept: Why Unilateral Upper Motor Neuron Lesions Rarely Cause Significant Dysarthria

Most cranial nerve motor nuclei receive bilateral corticobulbar innervation. This means:

A unilateral stroke affecting the corticobulbar tract typically causes only mild, transient dysarthria
Significant spastic dysarthria requires bilateral upper motor neuron damage
Exception: The lower face (CN VII) and tongue (CN XII) receive predominantly contralateral innervation — unilateral lesions can cause noticeable facial droop and tongue deviation

This is why spastic dysarthria is seen in conditions affecting both hemispheres (bilateral strokes, motor neuron disease, cerebral palsy) rather than unilateral stroke.

How Specific Conditions Cause Dysarthria

Condition	Mechanism	Clinical Implication
Parkinson disease	Dopamine depletion in substantia nigra → reduced basal ganglia output → hypokinesia affecting speech muscles	May respond to levodopa; speech therapy focusing on loudness (LSVT LOUD) effective
Amyotrophic lateral sclerosis	Progressive degeneration of both upper and lower motor neurons → mixed flaccid-spastic pattern	Progressive; early referral for augmentative communication essential
Myasthenia gravis	Antibodies block acetylcholine receptors → neuromuscular transmission failure → fatigable weakness	Characteristic fatigability pattern; dysarthria worsens with prolonged speaking; improves with rest
Multiple sclerosis	Demyelination in variable locations → may affect cerebellar, corticobulbar, or brainstem pathways	Pattern depends on lesion location; may change with relapses and remissions
Stroke	Ischemia or hemorrhage → acute neuronal damage; location determines type	Acute onset is hallmark; recovery depends on extent and location
Cerebellar degeneration	Loss of cerebellar Purkinje cells → impaired coordination of timing and force	Ataxic dysarthria; scanning speech is characteristic
Wilson disease	Copper deposition in basal ganglia and other brain regions → mixed movement disorder	May have mixed dysarthria; treatable cause — always consider in young patients

Often Overlooked Mechanism: Fatigable Dysarthria in Myasthenia Gravis

Myasthenia gravis produces a distinctive pattern that is often missed:

Speech is normal initially but deteriorates with sustained talking
Voice becomes progressively more hypernasal and breathy
Counting aloud from 1 to 100 may demonstrate progressive deterioration
After rest, speech quality improves

Clinical tip: If you suspect myasthenia gravis, have the patient count aloud or read continuously for 2-3 minutes and listen for worsening quality. This fatigable pattern is highly specific.

Complications and Secondary Effects of Dysarthria

Communication Breakdown

Severe dysarthria can lead to complete inability to communicate verbally, requiring augmentative and alternative communication (AAC) strategies including communication boards, text-to-speech devices, or eye-gaze systems.

Aspiration Risk

Many conditions causing dysarthria also affect swallowing (dysphagia). Weakness of the same muscles can impair airway protection, leading to aspiration pneumonia — a leading cause of death in conditions like amyotrophic lateral sclerosis and Parkinson disease.

3. History Taking

A comprehensive approach to eliciting the dysarthria history

Red Flags — Require Urgent Evaluation

Sudden onset dysarthria — Stroke until proven otherwise; activate stroke protocol
Associated facial droop or limb weakness — Stroke or acute neurological emergency
Dysarthria with dysphagia and respiratory distress — Impending airway compromise; may indicate myasthenic crisis or bulbar crisis
Rapidly progressive over days to weeks — Guillain-Barré syndrome, myasthenia gravis, brainstem lesion, or encephalitis

Associated altered consciousness or confusion — Metabolic encephalopathy, intoxication, or structural brain lesion
New headache with dysarthria — Intracranial hemorrhage, mass lesion, or elevated intracranial pressure
Dysarthria with diplopia and ptosis — Myasthenia gravis or brainstem stroke
Young patient with tremor and psychiatric symptoms — Wilson disease; requires urgent copper studies

Systematic History: The “SPEECH” Approach

Use the mnemonic “SPEECH” to ensure comprehensive history taking for dysarthria:

S — Start and Speed: When did it begin? How quickly did it develop? Sudden, gradual, or stepwise?
P — Pattern and Progression: Is it constant, fluctuating, or episodic? Getting worse, stable, or improving?
E — Extra neurological symptoms: Any weakness, numbness, vision changes, swallowing problems, or movement abnormalities?
E — Exacerbating and relieving factors: Worse with fatigue, time of day, temperature, or medications? Better after rest?
C — Character of speech change: How would they describe it? Slurred, quiet, nasal, effortful, or variable?
H — History (medical, family, medications): Prior strokes, neurological disease, family history, current medications?

Characterizing the Onset

Onset Pattern	Time Course	Suggests	Key Follow-up Questions
Sudden (seconds to minutes)	Maximal deficit at onset	Stroke, transient ischemic attack, seizure, hypoglycemia	“What were you doing when it started? Did you notice any other symptoms at exactly the same time?”
Acute (hours to days)	Rapid development	Guillain-Barré syndrome, encephalitis, drug toxicity, metabolic disturbance	“Has it been getting worse hour by hour? Any recent infections or new medications?”
Subacute (weeks)	Progressive over weeks	Myasthenia gravis, brain tumor, inflammatory conditions	“Has the change been steady or stepwise? Any fluctuation throughout the day?”
Chronic (months to years)	Insidious progression	Parkinson disease, amyotrophic lateral sclerosis, progressive supranuclear palsy, cerebellar degeneration	“When did your family first notice the change? Has anyone said your voice sounds different?”

Targeted Questions by Suspected Cause

Suspected Cause	Key Features to Elicit	Ask This Question
Stroke	Sudden onset, focal deficits, vascular risk factors	“Did the slurred speech come on suddenly? Did you notice any weakness, numbness, or vision changes at the same time?”
Parkinson disease	Soft voice, tremor, slowness, stiffness	“Has your voice become quieter? Do people ask you to repeat yourself? Have you noticed any shaking or slowness of movement?”
Myasthenia gravis	Fatigability, fluctuation, ptosis, diplopia	“Does your speech get worse the longer you talk? Is it better in the morning and worse by evening? Any droopy eyelids or double vision?”
Amyotrophic lateral sclerosis	Progressive weakness, fasciculations, no sensory symptoms	“Have you noticed any muscle twitching? Any weakness in your arms or legs? Any choking or difficulty swallowing?”
Multiple sclerosis	Relapsing symptoms, young patient, prior episodes	“Have you had episodes of neurological symptoms before that came and went? Any vision problems, numbness, or weakness in the past?”
Cerebellar disease	Coordination problems, unsteady gait, scanning speech	“Have you become unsteady on your feet? Any trouble with coordination or clumsiness? Has your handwriting changed?”
Drug-induced	Temporal relationship to medication	“Have you started any new medications recently? Does the slurred speech seem related to when you take your medications?”
Wilson disease	Young onset, psychiatric symptoms, liver disease, movement disorder	“Have you had any liver problems? Any mood changes or difficulty with thinking? Any tremor or unusual movements?”
Alcohol intoxication or withdrawal	Temporal relationship to alcohol use	“How much alcohol do you drink? Is the slurred speech related to drinking? Any shaking or confusion when you haven’t had a drink?”

Critical Associated Symptoms to Ask About

Bulbar Symptoms

Dysphagia: “Do you have trouble swallowing food or liquids? Do you choke or cough when eating?”
Drooling: “Do you notice saliva pooling in your mouth or drooling?”
Voice changes: “Has your voice become hoarse, breathy, or nasal?”
Aspiration: “Do you cough during or after meals? Any recent pneumonia?”

Other Neurological Symptoms

Weakness: “Any weakness in your face, arms, or legs?”
Sensory changes: “Any numbness, tingling, or unusual sensations?”
Vision: “Any double vision, blurred vision, or droopy eyelids?”
Gait: “Any trouble walking or balance problems?”
Cognition: “Any memory problems or confusion?”

Assessing Fluctuation Patterns

Fluctuation Is Diagnostically Important

The pattern of fluctuation can point directly to the diagnosis:

Worse with prolonged speaking, better after rest: Highly suggestive of myasthenia gravis
Worse when levodopa wears off, better after dose: Parkinson disease with motor fluctuations
Worse in the morning, improves through day: Consider sleep-related issues or morning stiffness in Parkinson disease
Worse with heat or exercise: Multiple sclerosis (Uhthoff phenomenon)
Episodic with complete recovery: Transient ischemic attack, migraine, or seizure
No fluctuation, constantly present: Structural lesion or stable deficit from prior stroke

Medication and Substance History

Medications That Can Cause Dysarthria

Sedatives and hypnotics: Benzodiazepines, barbiturates, zolpidem — dose-dependent central nervous system depression
Antiepileptic drugs: Phenytoin, carbamazepine, valproate — particularly at toxic levels
Antipsychotics: Can cause drug-induced parkinsonism or tardive dyskinesia
Lithium: Toxicity causes cerebellar dysfunction and tremor
Opioids: Central nervous system depression at high doses
Muscle relaxants: Baclofen, tizanidine — especially with dose increases
Chemotherapy agents: Some cause peripheral neuropathy affecting speech muscles

Substances and Exposures

Alcohol: Acute intoxication; chronic use causes cerebellar degeneration
Recreational drugs: Cannabis, sedatives, dissociatives
Heavy metals: Lead, mercury, manganese — occupational exposure
Carbon monoxide: Can cause basal ganglia damage
Organic solvents: Occupational or recreational exposure

Medications for Underlying Conditions

Levodopa timing: In Parkinson disease — note relationship of speech to medication schedule
Immunosuppressants: In myasthenia gravis — compliance and effectiveness

Relevant Medical and Family History

History Category	Key Points to Elicit	Relevance
Vascular risk factors	Hypertension, diabetes, hyperlipidemia, smoking, atrial fibrillation, prior stroke or transient ischemic attack	Increases likelihood of stroke as etiology
Neurological history	Prior stroke, head injury, brain surgery, known neurological conditions	May explain current symptoms or suggest recurrence
Autoimmune history	Thyroid disease, rheumatoid arthritis, lupus, other autoimmune conditions	Associated with myasthenia gravis and other autoimmune neurological conditions
Cancer history	Any malignancy, especially lung cancer	Paraneoplastic syndromes, brain metastases, Lambert-Eaton myasthenic syndrome
Family history	Parkinson disease, Huntington disease, spinocerebellar ataxia, muscular dystrophy, Wilson disease	Many causes of dysarthria have genetic components
Psychiatric history	Depression, anxiety, psychosis, personality changes	Wilson disease, Huntington disease, and some frontal lesions present with psychiatric symptoms

Assessing Functional Impact

Don’t Forget the Functional Assessment

Understanding the impact on daily life guides management and referrals:

Communication: “Can people understand you on the phone? In person? In noisy environments?”
Work: “Has this affected your job? Do you need to communicate verbally for work?”
Social: “Are you avoiding social situations because of your speech? Do you feel embarrassed or frustrated?”
Safety: “Could you call for help in an emergency?”
Mood: “How has this affected your mood? Do you feel isolated or depressed?”

4. Physical Examination

A systematic approach to examining the patient with dysarthria

Systematic Framework: Examine the patient systematically from general observation through a complete neurological examination. The goal is to identify the dysarthria type, localize the lesion, and detect associated neurological findings that point to the underlying etiology.

General Inspection

Level of consciousness: Alert, drowsy, or obtunded? Altered consciousness suggests metabolic, toxic, or acute structural cause
Respiratory pattern: Labored breathing, use of accessory muscles, or paradoxical breathing suggests respiratory muscle involvement
Posture: Stooped posture (Parkinson disease), abnormal head position (dystonia), or postural instability
Spontaneous movements: Tremor at rest (Parkinson disease), chorea (Huntington disease), dystonic posturing, or fasciculations
Facial expression: Masked facies (Parkinson disease), facial asymmetry (stroke, Bell palsy), or expressionless face
Drooling: Suggests poor oral motor control; common in Parkinson disease and bulbar palsy

Vital Signs

Vital Sign	What to Look For	Clinical Significance
Blood Pressure	Hypertension, hypotension, orthostatic changes	Hypertension is a stroke risk factor; orthostatic hypotension seen in Parkinson disease and multiple system atrophy
Heart Rate and Rhythm	Irregular rhythm (atrial fibrillation)	Atrial fibrillation is a major risk factor for cardioembolic stroke
Respiratory Rate	Tachypnea, shallow breathing, use of accessory muscles	Respiratory muscle weakness in myasthenia gravis, amyotrophic lateral sclerosis, or Guillain-Barré syndrome
Oxygen Saturation	Hypoxia	May indicate aspiration, respiratory muscle weakness, or impending respiratory failure
Temperature	Fever	Infection (aspiration pneumonia, encephalitis) or inflammatory process

Formal Speech Assessment

Components of Speech to Evaluate

Listen systematically to each component of speech production:

Respiration: Adequate breath support? Short phrases? Running out of air?
Phonation: Voice quality — breathy, harsh, strained, or tremulous? Pitch — too high, too low, or monotone?
Resonance: Hypernasal (air escaping through nose)? Hyponasal (blocked nasal passages)?
Articulation: Precision of consonants and vowels? Slurred or imprecise?
Prosody: Rate, rhythm, stress patterns — monotone, scanning, or inappropriately fast/slow?

Speech Tasks to Perform

Task	What to Say/Do	What to Listen For
Sustained vowel	“Say ‘ahh’ for as long as you can”	Voice quality (breathy, harsh, tremor); duration (reduced in respiratory weakness)
Alternating motion rate (AMR)	“Say ‘puh-puh-puh,’ ‘tuh-tuh-tuh,’ and ‘kuh-kuh-kuh’ as fast as you can”	Regular rate and rhythm? Irregular in ataxic dysarthria; slow in spastic/hypokinetic
Sequential motion rate (SMR)	“Say ‘puh-tuh-kuh’ over and over as fast as you can”	Coordination of different articulators; impaired in ataxic dysarthria and apraxia of speech
Sentence repetition	“The quick brown fox jumps over the lazy dog” or “Buy Bobby a puppy”	Overall intelligibility, articulation precision, prosody
Counting	“Count from 1 to 20” or “Count from 1 to 100” (for fatigability)	Consistency vs progressive deterioration (myasthenia gravis)
Reading passage	Have patient read a standard paragraph (e.g., “Rainbow Passage”)	Sustained performance; reveals prosodic abnormalities
Conversation	Open-ended questions about their history	Natural speech in context; intelligibility in real communication

Characteristic Speech Patterns by Dysarthria Type

Type	Key Auditory Features	Mnemonics/Descriptors
Flaccid	Breathy voice, hypernasality, nasal emission, short phrases, audible inspiration	“Breathy and nasal” — air escaping where it shouldn’t
Spastic	Strained-strangled voice, slow rate, imprecise consonants, hypernasality, monotone	“Effortful and strangled” — pushing through tight muscles
Ataxic	Irregular articulatory breakdowns, excess and equal stress, scanning speech, prolonged phonemes	“Drunk-sounding” — like speaking with alcohol intoxication
Hypokinetic	Monopitch, monoloudness, reduced stress, short rushes of speech, soft voice (hypophonia)	“Quiet and monotone” — reduced volume and variation
Hyperkinetic (chorea)	Variable rate, prolonged intervals, inappropriate silences, voice arrests, transient breathiness	“Interrupted and variable” — involuntary movements disrupt speech
Hyperkinetic (dystonia)	Strained voice, voice tremor, pitch breaks, slowness	“Strained with breaks” — muscle spasms interrupt voice

Cranial Nerve Examination for Speech

Trigeminal Nerve (CN V) — Jaw Function

Inspection: Jaw position at rest; any deviation?
Palpation: Feel masseter and temporalis muscles while patient clenches teeth — bulk, symmetry, strength
Function: Open jaw against resistance; side-to-side jaw movement
Abnormal finding: Jaw deviates to weak side when opening (lower motor neuron); wasting of temporalis (bulbar amyotrophic lateral sclerosis)

Facial Nerve (CN VII) — Lip and Face Function

Inspection: Facial symmetry at rest; nasolabial fold depth; palpebral fissure width
Function: Raise eyebrows, close eyes tightly, smile, puff cheeks, purse lips
Upper vs lower motor neuron: Upper motor neuron spares forehead (bilateral innervation); lower motor neuron affects entire hemiface
Abnormal finding: Facial droop, inability to seal lips, asymmetric smile

Glossopharyngeal and Vagus Nerves (CN IX, X) — Palate and Pharynx

Inspection: Observe palate at rest and during phonation (“say ahh”)
Normal: Palate elevates symmetrically and midline uvula
Unilateral weakness: Palate elevates asymmetrically; uvula deviates to strong side
Gag reflex: Touch posterior pharynx bilaterally — note symmetry (absent gag can be normal in some individuals)
Voice quality: Hoarseness or breathiness suggests vocal fold weakness
Cough: Ask patient to cough — weak, bovine cough suggests vocal fold paralysis

Hypoglossal Nerve (CN XII) — Tongue Function

Inspection at rest: Look for atrophy (particularly lateral margins), fasciculations (ask patient to relax tongue in floor of mouth)
Protrusion: “Stick out your tongue” — note deviation
Lower motor neuron lesion: Tongue deviates toward weak/atrophied side; fasciculations present
Upper motor neuron lesion: Tongue may deviate away from lesion; no atrophy or fasciculations; slow movements
Strength: Push tongue against cheek while you resist externally
Rapid movements: “Move your tongue side to side as fast as you can”

Critical Finding: Fasciculations with Atrophy

Tongue fasciculations combined with atrophy strongly suggest lower motor neuron disease. In the context of dysarthria with upper motor neuron signs elsewhere (hyperreflexia, spasticity), this combination is highly suggestive of amyotrophic lateral sclerosis. This finding warrants urgent neurological referral.

Motor Examination Beyond Speech

Finding	How to Test	Significance for Dysarthria Localization
Tone	Passive movement of limbs at major joints	Increased (spasticity/rigidity) → upper motor neuron or basal ganglia; Decreased → lower motor neuron
Bulk	Inspection and comparison of muscle mass	Atrophy → lower motor neuron disease or disuse
Power	Test major muscle groups against resistance	Pattern of weakness helps localize (pyramidal, peripheral nerve, myopathic)
Reflexes	Test deep tendon reflexes; look for pathological reflexes	Hyperreflexia with upgoing plantars → upper motor neuron; Hyporeflexia → lower motor neuron
Fasciculations	Observe muscles at rest, particularly tongue and limbs	Suggest lower motor neuron disease; prominent in amyotrophic lateral sclerosis
Bradykinesia	Rapid alternating movements, finger tapping, toe tapping	Slow, decreasing amplitude → Parkinson disease
Tremor	Observe at rest, with posture, during action	Rest tremor → Parkinson disease; Intention tremor → cerebellar disease
Chorea/Dystonia	Observe for involuntary movements	Hyperkinetic movement disorders affecting basal ganglia

Cerebellar Examination

Limb Coordination

Finger-nose-finger: Intention tremor, past-pointing
Heel-shin: Coordination of lower limbs
Rapid alternating movements: Dysdiadochokinesia

Truncal and Gait

Gait: Wide-based, ataxic gait
Tandem walking: Difficulty with heel-to-toe walking
Romberg test: Truncal ataxia (note: positive Romberg suggests sensory ataxia)

Eye Examination

Finding	How to Test	Associated Condition
Ptosis	Observe eyelid position at rest; fatigability with sustained upgaze	Myasthenia gravis (fatigable), Horner syndrome, oculomotor palsy
Diplopia/Ophthalmoplegia	Test extraocular movements in all directions	Myasthenia gravis, brainstem stroke, multiple sclerosis
Nystagmus	Observe for rhythmic eye movements on lateral and vertical gaze	Cerebellar disease, brainstem lesion, vestibular dysfunction
Kayser-Fleischer rings	Slit-lamp examination (refer to ophthalmology)	Wilson disease — copper deposition in cornea
Slow saccades	Ask patient to look quickly between two targets	Progressive supranuclear palsy, Huntington disease
Vertical gaze palsy	Test vertical eye movements, especially downgaze	Progressive supranuclear palsy (early downgaze limitation)

Expected Examination Findings by Etiology

Condition	Speech Pattern	Cranial Nerve Findings	Other Key Findings
Stroke (unilateral)	Mild dysarthria or none (due to bilateral innervation)	Contralateral lower facial weakness, possible tongue deviation	Hemiparesis, hemisensory loss, visual field defect
Stroke (bilateral/brainstem)	Spastic or flaccid depending on level	Bilateral facial weakness, palatal weakness, tongue weakness	Pseudobulbar affect, dysphagia, quadriparesis possible
Parkinson disease	Hypokinetic — soft, monotone, fast with festination	Masked facies, reduced blink rate	Rest tremor, rigidity, bradykinesia, shuffling gait
Amyotrophic lateral sclerosis	Mixed flaccid-spastic	Tongue atrophy and fasciculations, jaw jerk brisk, emotional lability	Both upper and lower motor neuron signs in limbs, fasciculations
Myasthenia gravis	Flaccid — fatigable, worsens with prolonged speech	Ptosis (fatigable), diplopia, weak palate elevation	Proximal limb weakness, fatigability, normal reflexes
Multiple sclerosis	Variable — often ataxic or mixed	Internuclear ophthalmoplegia, nystagmus	Multiple neurological deficits, sensory symptoms, Lhermitte sign
Cerebellar degeneration	Ataxic — scanning, irregular	Nystagmus (often horizontal)	Limb ataxia, gait ataxia, dysdiadochokinesia
Huntington disease	Hyperkinetic — variable, interrupted	Oculomotor abnormalities, slow saccades	Chorea, cognitive decline, psychiatric symptoms
Wilson disease	Mixed — often dystonic component	Kayser-Fleischer rings (requires slit lamp)	Tremor, dystonia, rigidity, psychiatric symptoms, hepatomegaly

Special Tests for Myasthenia Gravis

Bedside Tests for Fatigability

Sustained counting test: Have patient count aloud from 1 to 100. Listen for progressive hypernasality, breathiness, and reduced volume.
Sustained upgaze test: Have patient look up for 1-2 minutes. Observe for developing or worsening ptosis.
Repeated eye closure: Ask patient to close eyes tightly repeatedly. Weakness develops with repetition.
Ice pack test: Apply ice to closed eyelid for 2 minutes. Improvement in ptosis supports myasthenia gravis (cold improves neuromuscular transmission).

Note: These bedside tests are screening tools. Positive findings should prompt formal testing with acetylcholine receptor antibodies and electrodiagnostic studies.

Important Teaching Point

The examination must go beyond speech! Dysarthria is a symptom of neurological disease. The physical examination should identify:

The type of dysarthria (flaccid, spastic, ataxic, hypokinetic, hyperkinetic, mixed)
The neuroanatomical localization (lower motor neuron, upper motor neuron, cerebellum, basal ganglia)
Associated findings that suggest the underlying diagnosis

A focused speech assessment combined with a complete neurological examination is essential for accurate diagnosis.

5. Differential Diagnosis

Systematic approach organized by probability, onset, and neuroanatomical localization

Acute Dysarthria (Onset within minutes to hours)

Acute Dysarthria Is a Medical Emergency

Sudden onset dysarthria should be treated as stroke until proven otherwise. Activate stroke protocols immediately if onset is within the treatment window.

Probability	Condition	Key Features	Red Flags
COMMON	Ischemic stroke	Sudden onset, focal neurological deficits, vascular risk factors	Time-critical — assess for thrombolysis/thrombectomy eligibility
COMMON	Transient ischemic attack	Symptoms resolve within 24 hours (usually minutes), same risk factors as stroke	High risk of subsequent stroke — urgent workup required
COMMON	Drug or alcohol intoxication	History of substance use, altered consciousness, other signs of intoxication	Do not assume intoxication without excluding stroke
LESS COMMON	Intracerebral hemorrhage	Severe headache, vomiting, rapid deterioration, hypertension	May require emergent neurosurgical intervention
LESS COMMON	Hypoglycemia	Diabetic patient, sweating, tremor, confusion, responds to glucose	Easily reversible — always check blood glucose
LESS COMMON	Seizure (postictal state)	Witnessed seizure activity, confusion, gradual improvement	May be first presentation of brain lesion
UNCOMMON BUT SERIOUS	Brainstem stroke	Cranial nerve deficits, crossed signs, vertigo, ataxia	May progress rapidly — posterior circulation strokes are easily missed
UNCOMMON BUT SERIOUS	Myasthenic crisis	Known myasthenia gravis, respiratory distress, worsening weakness	Respiratory failure imminent — ICU admission required
UNCOMMON BUT SERIOUS	Basilar artery occlusion	Decreased consciousness, bilateral motor deficits, “locked-in” syndrome	Life-threatening — emergent intervention may be indicated

Subacute Dysarthria (Onset over days to weeks)

Clinical Approach to Subacute Dysarthria:

Step 1: Exclude medication or toxic cause — review all medications, check drug levels if applicable
Step 2: Consider inflammatory or autoimmune conditions — myasthenia gravis, Guillain-Barré syndrome, multiple sclerosis
Step 3: Rule out structural lesion — brain imaging to exclude tumor or abscess
Step 4: Consider infectious causes — encephalitis, brain abscess

Probability	Condition	Approximate Frequency	Key Distinguishing Features
COMMON	Myasthenia gravis	Most common neuromuscular junction disorder	Fatigability — worse with prolonged use, better after rest; ptosis, diplopia; no sensory symptoms
COMMON	Medication-induced	Common in polypharmacy patients	Temporal relationship to medication initiation or dose change; reversible
LESS COMMON	Brain tumor	Variable	Progressive symptoms, headache, seizures, focal deficits depending on location
LESS COMMON	Multiple sclerosis relapse	Peak incidence age 20-40	Prior neurological episodes, sensory symptoms, Lhermitte sign, internuclear ophthalmoplegia
LESS COMMON	Guillain-Barré syndrome (bulbar variant)	1-2 per 100,000 annually	Preceding infection, ascending weakness, areflexia, may have facial weakness
UNCOMMON BUT SERIOUS	Encephalitis	Rare	Fever, altered consciousness, seizures, psychiatric symptoms
UNCOMMON BUT SERIOUS	Brain abscess	Rare	Fever, headache, focal deficits, risk factors (endocarditis, sinusitis, immunocompromise)
UNCOMMON BUT SERIOUS	Brainstem tumor	Rare in adults	Multiple cranial nerve palsies, long tract signs, progressive course

Chronic Progressive Dysarthria (Onset over months to years)

Step-by-Step Approach to Chronic Progressive Dysarthria:

Step 1: Identify the dysarthria type — this localizes the lesion
Step 2: Look for the “Big Five” neurodegenerative causes — Parkinson disease, amyotrophic lateral sclerosis, multiple sclerosis, progressive supranuclear palsy, cerebellar degeneration
Step 3: Consider treatable causes in young patients — Wilson disease (always consider in patients under age 50)
Step 4: Investigate for less common hereditary or acquired causes if initial workup is negative

Probability	Condition	Dysarthria Type	Key Distinguishing Features
COMMON	Parkinson disease	Hypokinetic	Rest tremor, rigidity, bradykinesia, shuffling gait, masked facies; typically asymmetric onset
COMMON	Prior stroke (chronic deficit)	Variable (often spastic if bilateral)	History of stroke, stable deficit, vascular risk factors
COMMON	Multiple sclerosis	Ataxic, spastic, or mixed	Relapsing-remitting course, multiple neurological deficits, young to middle-aged patients
LESS COMMON	Amyotrophic lateral sclerosis	Mixed flaccid-spastic	Progressive weakness without sensory loss, fasciculations, upper and lower motor neuron signs
LESS COMMON	Progressive supranuclear palsy	Hypokinetic or spastic	Vertical gaze palsy (especially downgaze), early falls, axial rigidity, poor levodopa response
LESS COMMON	Multiple system atrophy	Hypokinetic, ataxic, or mixed	Autonomic dysfunction (orthostatic hypotension, urinary symptoms), poor levodopa response, cerebellar signs
LESS COMMON	Spinocerebellar ataxia	Ataxic	Family history, progressive ataxia, may have additional features depending on subtype
UNCOMMON BUT TREATABLE	Wilson disease	Mixed (often dystonic)	Age under 50, Kayser-Fleischer rings, liver disease, psychiatric symptoms, tremor
UNCOMMON	Huntington disease	Hyperkinetic	Family history, chorea, cognitive decline, psychiatric symptoms
UNCOMMON	Primary lateral sclerosis	Spastic	Pure upper motor neuron syndrome, very slow progression, no lower motor neuron signs
UNCOMMON	Corticobasal degeneration	Spastic or mixed	Asymmetric rigidity and apraxia, alien limb phenomenon, cortical sensory loss

Anatomical Approach to Differential Diagnosis

Upper Motor Neuron (Spastic)

Bilateral stroke

Primary lateral sclerosis

Cerebral palsy

Multiple sclerosis

Amyotrophic lateral sclerosis (upper motor neuron component)

Lower Motor Neuron (Flaccid)

Myasthenia gravis

Guillain-Barré syndrome

Brainstem stroke

Amyotrophic lateral sclerosis (bulbar onset)

Cranial neuropathies

Muscular dystrophy

Cerebellum (Ataxic)

Cerebellar stroke

Multiple sclerosis

Spinocerebellar ataxia

Alcohol-related cerebellar degeneration

Paraneoplastic cerebellar degeneration

Friedreich ataxia

Basal Ganglia (Hypo/Hyperkinetic)

Parkinson disease

Progressive supranuclear palsy

Multiple system atrophy

Huntington disease

Wilson disease

Drug-induced parkinsonism

Dystonia

Drug-Induced Dysarthria

Drug or Drug Class	Mechanism	Characteristics	Time to Resolution After Stopping
Benzodiazepines	Central nervous system depression, cerebellar effects	Dose-dependent, ataxic-type speech, sedation	Hours to days (depends on half-life)
Antiepileptic drugs (phenytoin, carbamazepine)	Cerebellar toxicity at high levels	Ataxic dysarthria, nystagmus, ataxia	Days to weeks; check drug levels
Lithium	Cerebellar toxicity, tremor	Ataxic speech, tremor, confusion at toxic levels	Days to weeks; some effects may be permanent
Antipsychotics (typical and atypical)	Dopamine blockade → parkinsonism; tardive dyskinesia	Hypokinetic (parkinsonism) or hyperkinetic (tardive)	Weeks to months; tardive may be permanent
Metoclopramide	Dopamine blockade	Drug-induced parkinsonism, tardive dyskinesia	Weeks to months after discontinuation
Opioids	Central nervous system depression	Slurred speech with sedation	Hours (depends on specific agent)
Alcohol	Acute: cerebellar suppression; Chronic: cerebellar degeneration	Acute: reversible ataxic speech; Chronic: permanent ataxic dysarthria	Acute: hours; Chronic: may be irreversible
Valproate	Tremor, possible cerebellar effects, encephalopathy	Tremor affecting speech, cognitive slowing	Days to weeks
Amiodarone	Peripheral neuropathy, cerebellar toxicity (rare)	May cause ataxic features with chronic use	Weeks to months (very long half-life)

Quick Reference: “If You See This, Think This”

Clinical Clue	Think This First	Next Step
Sudden onset with hemiparesis	Stroke	Activate stroke protocol, emergent CT head
Fatigable dysarthria with ptosis	Myasthenia gravis	Acetylcholine receptor antibodies, ice pack test, consider edrophonium test
Soft monotone voice with rest tremor	Parkinson disease	Trial of levodopa, dopamine transporter scan if uncertain
Scanning speech with gait ataxia	Cerebellar disease	MRI brain focusing on posterior fossa, consider paraneoplastic antibodies
Mixed dysarthria with fasciculations	Amyotrophic lateral sclerosis	Electromyography, exclude structural lesion with MRI
Dysarthria with vertical gaze palsy and falls	Progressive supranuclear palsy	MRI (midbrain atrophy), poor response to levodopa
Young patient with tremor and psychiatric symptoms	Wilson disease	Serum ceruloplasmin, 24-hour urine copper, slit-lamp examination
Dysarthria with chorea and family history	Huntington disease	Genetic testing for CAG repeat expansion
Relapsing-remitting symptoms in young adult	Multiple sclerosis	MRI brain and spine with contrast, lumbar puncture for oligoclonal bands
Dysarthria worse with new medication	Drug-induced	Review medications, check drug levels, trial of discontinuation

Age-Based Differential Considerations

Young Adults (18-40 years)

Multiple sclerosis
Wilson disease (always consider if under 50)
Drug or alcohol intoxication
Myasthenia gravis
Traumatic brain injury
Young-onset Parkinson disease (rare)
Hereditary ataxias

Older Adults (over 60 years)

Stroke and cerebrovascular disease
Parkinson disease
Progressive supranuclear palsy
Amyotrophic lateral sclerosis
Multiple system atrophy
Drug-induced (polypharmacy)
Paraneoplastic syndromes

6. Diagnostic Investigations

A stepwise, cost-effective approach guided by clinical suspicion

Baseline Investigations for All Patients with Unexplained Dysarthria

Investigation	Purpose	What to Look For	Practical Points
Blood glucose	Exclude hypoglycemia	Low glucose (below 70 mg/dL or 3.9 mmol/L)	Check immediately in acute presentation; easily reversible cause
Complete blood count	Screen for infection, anemia, malignancy	Elevated white cell count, anemia, thrombocytosis	Infection may worsen underlying neurological conditions
Basic metabolic panel	Electrolytes, renal function	Sodium abnormalities, uremia	Metabolic encephalopathy can cause dysarthria
Liver function tests	Hepatic encephalopathy, Wilson disease screening	Elevated transaminases, low albumin	Wilson disease may present with liver dysfunction
Thyroid function tests	Thyroid dysfunction can affect speech and is associated with myasthenia gravis	Hypothyroidism or hyperthyroidism	Thyroid disease is common comorbidity with myasthenia gravis
CT head (non-contrast)	Exclude acute hemorrhage, mass lesion, hydrocephalus	Hemorrhage, mass effect, infarct (may be subtle early)	First-line imaging in acute setting; MRI superior for most pathology
MRI brain	Detailed structural imaging	Infarcts, demyelination, atrophy patterns, masses	Superior to CT for posterior fossa, white matter disease, subtle lesions

Imaging Considerations

Acute presentation: CT head first to exclude hemorrhage; follow with MRI if CT non-diagnostic
Subacute or chronic: MRI brain is preferred initial imaging
Include posterior fossa: Many causes of dysarthria involve brainstem or cerebellum
Consider MRI sequences: Diffusion-weighted imaging for acute stroke; FLAIR for demyelination; T2* or susceptibility-weighted imaging for microhemorrhages

Targeted Investigations by Suspected Etiology

If Suspecting Stroke or Cerebrovascular Disease

Acute Stroke Workup

CT head: Immediate — exclude hemorrhage before thrombolysis
CT angiography: Large vessel occlusion assessment for thrombectomy
MRI with diffusion-weighted imaging: Most sensitive for acute infarction
ECG: Atrial fibrillation detection
Echocardiogram: Cardiac source of embolism
Carotid ultrasound: Carotid stenosis

Risk Factor Assessment

Lipid profile: Hyperlipidemia
HbA1c: Diabetes screening
Holter monitor: Paroxysmal atrial fibrillation (if ECG normal)
Hypercoagulability panel: In young patients without traditional risk factors

If Suspecting Myasthenia Gravis

First-Line Tests

Acetylcholine receptor (AChR) antibodies: Positive in approximately 85% of generalized myasthenia gravis, approximately 50% of ocular myasthenia gravis
Anti-muscle-specific kinase (MuSK) antibodies: Check if AChR negative; more common in bulbar-predominant disease
CT chest: Thymoma screening — present in 10-15% of myasthenia gravis patients

Second-Line Tests

Repetitive nerve stimulation: Decremental response greater than 10% is abnormal
Single-fiber electromyography: Most sensitive test; increased jitter
Edrophonium (Tensilon) test: Rarely used now; improvement with anticholinesterase
Anti-LRP4 antibodies: If seronegative for AChR and MuSK

If Suspecting Parkinson Disease or Parkinsonism

Diagnosis Is Primarily Clinical

Clinical response to levodopa: Robust response supports idiopathic Parkinson disease
MRI brain: Exclude structural causes; may show specific patterns in atypical parkinsonism

If Diagnosis Uncertain

DaTscan (dopamine transporter imaging): Distinguishes Parkinson disease from essential tremor or drug-induced parkinsonism
Autonomic function testing: If multiple system atrophy suspected

If Suspecting Amyotrophic Lateral Sclerosis

First-Line Tests

Electromyography (EMG) and nerve conduction studies: Widespread denervation with normal sensory studies; fibrillations and fasciculations
MRI brain and cervical spine: Exclude structural mimics (cervical myelopathy, foramen magnum lesions)

Exclusionary Tests

Anti-GM1 antibodies: Multifocal motor neuropathy (treatable mimic)
Serum protein electrophoresis: Paraproteinemia
HIV and HTLV-1: In appropriate risk groups
Lead level: If exposure history

If Suspecting Multiple Sclerosis

First-Line Tests

MRI brain and spine with contrast: Periventricular, juxtacortical, infratentorial, and spinal cord lesions; gadolinium enhancement indicates active inflammation
Lumbar puncture: Oligoclonal bands (present in greater than 95%), elevated IgG index

Supporting Tests

Visual evoked potentials: Prolonged P100 latency suggests optic nerve demyelination
Optical coherence tomography: Retinal nerve fiber layer thinning
Aquaporin-4 and MOG antibodies: Exclude neuromyelitis optica spectrum disorder

If Suspecting Wilson Disease

Always Consider Wilson Disease in Patients Under Age 50

Wilson disease is treatable but fatal if untreated. Screen any patient under 50 with unexplained dysarthria, movement disorder, psychiatric symptoms, or liver disease.

Screening Tests

Serum ceruloplasmin: Low in most cases (below 20 mg/dL)
24-hour urine copper: Elevated (greater than 100 mcg/24 hours)
Serum copper: Total may be low; free copper is elevated

Confirmatory Tests

Slit-lamp examination: Kayser-Fleischer rings (copper in Descemet membrane)
Liver biopsy: Hepatic copper content greater than 250 mcg/g dry weight
Genetic testing: ATP7B gene mutations
MRI brain: “Face of the giant panda” sign in midbrain

If Suspecting Cerebellar Disease

First-Line Tests

MRI brain: Cerebellar atrophy, lesions, or structural abnormalities
Vitamin B12 and folate: Nutritional deficiency
Vitamin E level: Deficiency causes ataxia
Thyroid function: Hypothyroidism can cause cerebellar dysfunction

Second-Line Tests

Paraneoplastic antibody panel: Anti-Yo, anti-Hu, anti-Tr (especially in smokers or with malignancy history)
CT chest/abdomen/pelvis: Occult malignancy if paraneoplastic suspected
Genetic testing: Spinocerebellar ataxia panel if hereditary pattern
Anti-GAD antibodies: Autoimmune cerebellar ataxia

Empiric Treatment Trials as Diagnostic Tools

Therapeutic Trials Can Aid Diagnosis

When diagnosis is uncertain, response to specific treatments can support the diagnosis:

Levodopa trial: Robust improvement in motor symptoms including speech supports Parkinson disease. Give adequate dose (up to 1000 mg/day) for adequate duration (at least 1 month) before concluding lack of response.
Pyridostigmine trial: Improvement in fatigable weakness supports myasthenia gravis. Objective measurement of speech during prolonged tasks before and after medication.
Medication withdrawal: If drug-induced cause suspected, discontinue offending agent and observe for improvement over appropriate time frame.

Stepwise Investigation Algorithm

Practical Approach Based on Presentation:

Acute onset (stroke suspected): Immediate CT head → CT angiography if thrombolysis/thrombectomy candidate → MRI within 24-48 hours → vascular workup
Subacute with fatigability: Acetylcholine receptor antibodies → CT chest → repetitive nerve stimulation or single-fiber EMG
Chronic progressive with parkinsonism: MRI brain → levodopa trial → DaTscan if uncertain → consider atypical parkinsonism workup
Chronic progressive with mixed upper and lower motor neuron signs: MRI brain and cervical spine → EMG/nerve conduction studies → exclude mimics
Any patient under 50 with movement disorder: Include Wilson disease screening (ceruloplasmin, 24-hour urine copper, slit-lamp examination)

Special Considerations

Population	Additional Considerations	Specific Tests
Young patients (under 50)	Higher yield for treatable and genetic causes	Wilson disease screening, genetic testing for hereditary ataxias, multiple sclerosis workup
Rapid progression	Consider aggressive or inflammatory causes	Paraneoplastic antibodies, autoimmune encephalitis panel, malignancy screening
Known malignancy	Paraneoplastic syndrome, brain metastases, treatment toxicity	MRI brain with contrast, paraneoplastic panel, review chemotherapy history
Immunocompromised	Opportunistic infections, progressive multifocal leukoencephalopathy	MRI brain, lumbar puncture for JC virus PCR, toxoplasmosis serology
Strong family history	Hereditary conditions more likely	Genetic counseling, specific genetic testing (Huntington, spinocerebellar ataxias)

7. Pattern Recognition and Clinical Decision-Making

Practical algorithms and decision pathways for dysarthria

Step 1: Is This Urgent?

Clinical Scenario	Urgency Level	Immediate Action
Sudden onset dysarthria with focal deficits (weakness, numbness, vision changes)	EMERGENT	Activate stroke protocol; immediate CT head; assess for thrombolysis/thrombectomy eligibility
Dysarthria with respiratory distress or declining respiratory function	EMERGENT	Secure airway; ICU admission; consider myasthenic crisis, Guillain-Barré syndrome, or bulbar amyotrophic lateral sclerosis crisis
Dysarthria with altered consciousness	EMERGENT	Check glucose; CT head; metabolic panel; consider intoxication, stroke, or encephalitis
Rapidly progressive dysarthria over days with dysphagia	URGENT	Admit for observation; myasthenia gravis workup; monitor respiratory function; swallow evaluation
New dysarthria with severe headache	URGENT	CT head to exclude hemorrhage; consider mass lesion or elevated intracranial pressure
Dysarthria with fatigability and ptosis	URGENT	Myasthenia gravis workup; assess respiratory function; acetylcholine receptor antibodies; CT chest for thymoma
Chronic progressive dysarthria without red flags	ROUTINE	Outpatient neurology referral; MRI brain; targeted workup based on dysarthria type and examination findings
Stable dysarthria following known prior stroke	ROUTINE	Speech therapy referral; secondary stroke prevention optimization; rehabilitation assessment

Step 2: Classify by Onset and Duration

Acute (Minutes to Hours)

Proceed to Algorithm A

Focus: Stroke, hypoglycemia, intoxication, seizure

Subacute (Days to Weeks)

Proceed to Algorithm B

Focus: Myasthenia gravis, inflammatory conditions, tumor

Chronic (Months to Years)

Proceed to Algorithm C

Focus: Neurodegenerative disease, identify dysarthria type

Step 3: Follow the Appropriate Algorithm

Algorithm A: Acute Onset Dysarthria

Clinical Scenario	Most Likely Diagnosis	Action
Sudden onset with hemiparesis, facial droop, or hemisensory loss	Ischemic stroke	Stroke protocol; CT head; consider thrombolysis if within window; CT angiography for thrombectomy evaluation
Sudden onset with severe headache, vomiting, hypertension	Intracerebral hemorrhage	CT head immediately; blood pressure management; neurosurgery consultation if indicated
Acute onset with vertigo, diplopia, ataxia, crossed signs	Brainstem or cerebellar stroke	MRI preferred (CT often misses posterior fossa strokes); urgent vascular imaging
Known diabetic with sweating, tremor, confusion	Hypoglycemia	Check blood glucose immediately; give glucose; symptoms should resolve rapidly
History of alcohol or sedative use; gradual resolution	Intoxication	Supportive care; do NOT assume intoxication without excluding stroke in at-risk patients
Witnessed seizure activity; postictal confusion; gradual improvement	Postictal state	Observation; consider brain imaging to exclude structural cause; EEG if first seizure

Algorithm B: Subacute Onset Dysarthria

Clinical Scenario	Most Likely Diagnosis	Action
Fatigable dysarthria; worse throughout day; ptosis; diplopia	Myasthenia gravis	Acetylcholine receptor antibodies; repetitive nerve stimulation; CT chest; monitor respiratory function
Progressive weakness starting distally; areflexia; recent infection	Guillain-Barré syndrome	Admit; lumbar puncture (albuminocytologic dissociation); monitor respiratory function; IVIG or plasmapheresis
New medication started; dose recently increased	Drug-induced	Review all medications; check drug levels if applicable; trial of dose reduction or discontinuation
Progressive headache; focal deficits; papilledema	Brain tumor or mass lesion	MRI brain with contrast; neurosurgery referral if mass identified
Young patient; prior neurological episodes; sensory symptoms	Multiple sclerosis	MRI brain and spine with contrast; lumbar puncture for oligoclonal bands
Fever; confusion; headache; behavioral changes	Encephalitis	MRI brain; lumbar puncture; empiric acyclovir while awaiting results

Algorithm C: Chronic Progressive Dysarthria

Dysarthria Type Identified	Most Likely Diagnoses	Action
Hypokinetic — soft, monotone, rapid with festination	Parkinson disease, progressive supranuclear palsy, multiple system atrophy	Levodopa trial; assess response; if poor response or atypical features, consider atypical parkinsonism
Ataxic — scanning, irregular, excess and equal stress	Cerebellar degeneration, multiple sclerosis, spinocerebellar ataxia	MRI brain (cerebellar atrophy pattern); paraneoplastic antibodies; genetic testing if hereditary pattern
Spastic — strained-strangled, slow, effortful	Primary lateral sclerosis, bilateral stroke, amyotrophic lateral sclerosis	MRI brain and spine; EMG to exclude lower motor neuron involvement; monitor for progression
Flaccid — breathy, hypernasal, weak	Myasthenia gravis, bulbar amyotrophic lateral sclerosis, brainstem lesion	If fatigable → myasthenia workup; if progressive with fasciculations → amyotrophic lateral sclerosis workup
Mixed flaccid-spastic	Amyotrophic lateral sclerosis	EMG (widespread denervation); MRI to exclude structural mimics; supportive care; early discussion of prognosis and advance care planning
Hyperkinetic — variable, interrupted by involuntary movements	Huntington disease, dystonia, tardive dyskinesia	Family history; genetic testing for Huntington disease; review medication history for tardive causes

“What Do I Do If…” Decision Reference

Clinical Situation	Immediate Action	Next Step
Patient is within stroke thrombolysis window	Do not delay for additional history; proceed with CT and stroke protocol	Thrombolysis decision based on CT findings and eligibility criteria; consider thrombectomy for large vessel occlusion
Suspected myasthenia gravis with respiratory symptoms	Admit to ICU; measure forced vital capacity; prepare for possible intubation	Forced vital capacity below 1 liter or negative inspiratory force less than -20 cm H2O → consider intubation; IVIG or plasmapheresis
Young patient (under 50) with unexplained dysarthria	Include Wilson disease in workup regardless of other findings	Ceruloplasmin, 24-hour urine copper, slit-lamp examination; Wilson disease is treatable if caught early
Dysarthria with dysphagia and weight loss	Urgent swallow evaluation; nutritional assessment	Consider PEG tube if aspiration risk is high; speech therapy for swallowing strategies
Dysarthria not responding to standard treatments	Reassess diagnosis; consider additional investigations	Was the diagnosis correct? Was treatment duration adequate? Are there multiple overlapping causes?
Patient on antipsychotics develops dysarthria	Assess for drug-induced parkinsonism vs tardive dyskinesia	If parkinsonism: reduce dose or switch to atypical agent; if tardive: discontinue if possible (may worsen initially)
Dysarthria severity makes communication impossible	Urgent speech therapy referral for augmentative and alternative communication	Assess for communication devices (text-to-speech, eye-gaze technology); involve family in communication strategies

When to Refer

Urgent Neurology Referral

Acute onset dysarthria (after stroke workup completed)
Rapidly progressive symptoms
Suspected amyotrophic lateral sclerosis (bulbar signs with upper and lower motor neuron findings)
Suspected myasthenia gravis
Young patient with unexplained dysarthria
Diagnostic uncertainty after initial workup

Routine Referrals

Speech-language pathology: All patients with dysarthria for assessment and therapy
Occupational therapy: Augmentative communication devices if needed
Dietitian: If dysphagia or nutritional concerns
Palliative care: Early involvement for progressive conditions like amyotrophic lateral sclerosis
Genetic counseling: If hereditary condition suspected

Troubleshooting Refractory Dysarthria

Ask These Questions When Dysarthria Is Not Improving

Is the diagnosis correct? Reassess dysarthria type; consider alternative diagnoses
Was the treatment adequate? Sufficient dose? Sufficient duration? (e.g., levodopa trial needs adequate dosing)
Is the patient adherent? Medication compliance? Attending speech therapy?
Are there multiple causes? Parkinson disease patient may also have stroke; medication effect may overlay primary disease
Is this a progressive condition? Some diseases (amyotrophic lateral sclerosis, progressive supranuclear palsy) will progress despite treatment — focus shifts to supportive care and quality of life
Has speech therapy been optimized? Specific programs like LSVT LOUD for Parkinson disease may be more effective than general speech therapy

8. Clinical Pearls and Pitfalls

Practical wisdom — learn from successes and avoid common mistakes

Must-Know Clinical Pearls

Dysarthria type equals neuroanatomical localization: Before ordering any imaging, identify the dysarthria type (flaccid, spastic, ataxic, hypokinetic, hyperkinetic, or mixed). This immediately narrows the differential and guides your workup.

Fatigability is the hallmark of myasthenia gravis: If speech worsens with prolonged talking and improves after rest, think myasthenia gravis. Have the patient count to 100 and listen for progressive deterioration — this simple test is highly specific.

Always consider Wilson disease in patients under 50: Wilson disease is rare but treatable. Any unexplained dysarthria, movement disorder, or psychiatric symptoms in a young patient should prompt screening with ceruloplasmin and 24-hour urine copper.

Tongue fasciculations plus atrophy is a red flag for amyotrophic lateral sclerosis: This combination indicates lower motor neuron involvement of the hypoglossal nerve. Combined with upper motor neuron signs (brisk jaw jerk, spasticity), it strongly suggests amyotrophic lateral sclerosis.

Unilateral upper motor neuron lesions rarely cause significant dysarthria: Most bulbar muscles receive bilateral corticobulbar innervation. Significant spastic dysarthria requires bilateral upper motor neuron damage — this is why it is seen in bilateral strokes, not unilateral stroke.

Scanning speech is cerebellar until proven otherwise: The combination of irregular articulatory breakdowns with excess and equal stress on syllables (scanning speech) localizes to the cerebellum. Look for other cerebellar signs: ataxia, nystagmus, intention tremor, dysdiadochokinesia.

LSVT LOUD works for Parkinson disease: Lee Silverman Voice Treatment (LSVT LOUD) is the most evidence-based speech therapy for hypokinetic dysarthria in Parkinson disease. It focuses on increasing vocal loudness and has proven long-term benefits.

Check the ears in unexplained cough with dysarthria: Arnold’s nerve (auricular branch of vagus) can trigger cough reflex. Ear wax, infection, or foreign body can cause chronic cough. This is also relevant in evaluating bulbar function — the vagus nerve serves both speech and ear sensation.

Critical Pitfalls to Avoid

Assuming slurred speech in an intoxicated patient is just intoxication: Alcohol-intoxicated patients can also have strokes. Always maintain a high index of suspicion for stroke in patients with acute dysarthria and vascular risk factors, regardless of intoxication status.

Confusing dysarthria with aphasia: Dysarthria is a motor speech problem (execution); aphasia is a language problem (formulation). A patient with dysarthria can write normally and understands language perfectly. This distinction changes the entire diagnostic approach.

Missing myasthenia gravis because initial examination is normal: Myasthenic weakness is fatigable. A patient examined early in the day after rest may appear normal. Always ask about fluctuation and examine after sustained effort (prolonged talking, sustained upgaze).

Concluding levodopa failure after inadequate trial: An adequate levodopa trial for Parkinson disease requires sufficient dose (up to 1000-1200 mg/day) for sufficient duration (at least 1-2 months). Many patients are labeled as “levodopa non-responders” when they never received an adequate trial.

Forgetting to assess respiratory function in bulbar disease: Dysarthria and dysphagia often coexist with respiratory muscle weakness. In myasthenia gravis, Guillain-Barré syndrome, and amyotrophic lateral sclerosis, respiratory failure can develop rapidly. Monitor forced vital capacity and negative inspiratory force.

Attributing all speech changes to the known diagnosis: A patient with Parkinson disease can also have a stroke. A patient with multiple sclerosis can develop drug-induced parkinsonism. Always consider whether new or changed symptoms fit the known diagnosis or represent a new problem.

Delaying referral to speech therapy: Early speech therapy intervention improves outcomes. Do not wait until dysarthria is severe — refer at first recognition. For progressive conditions, early involvement also allows time to introduce augmentative communication before it becomes urgent.

Overlooking medication causes: Drug-induced dysarthria is common and reversible. Review all medications, especially sedatives, antiepileptics, antipsychotics, and lithium. Check drug levels when applicable. A simple medication adjustment may resolve the problem.

Key Takeaways

Acute dysarthria is a stroke until proven otherwise — activate stroke protocols for sudden onset; do not delay imaging for detailed history
Identify the dysarthria type first — flaccid, spastic, ataxic, hypokinetic, hyperkinetic, or mixed; this localizes the lesion and guides diagnosis
Fatigability pattern points to myasthenia gravis — worsening with use, improvement with rest; test with prolonged counting or sustained upgaze
Wilson disease is treatable — always screen young patients (under 50) with unexplained dysarthria or movement disorder
Mixed flaccid-spastic dysarthria suggests amyotrophic lateral sclerosis — look for fasciculations, atrophy, and both upper and lower motor neuron signs
Dysarthria is not aphasia — language comprehension and formulation are intact in dysarthria; writing is preserved; the problem is motor execution
Always assess for dysphagia and respiratory function — these commonly coexist with dysarthria in bulbar disease and determine urgency and prognosis
Review medications in every patient — drug-induced dysarthria is common and reversible; always check levels for drugs with narrow therapeutic windows
Speech therapy helps — refer early; specific programs (like LSVT LOUD for Parkinson disease) are more effective than generic therapy
Consider augmentative communication early — for progressive conditions, introduce communication aids before speech becomes unintelligible

Quick Reference Algorithm

Systematic Approach to Dysarthria:

Assess urgency: Acute onset → stroke protocol; respiratory distress → secure airway; altered consciousness → check glucose, CT head
Distinguish from aphasia: Can the patient write? Do they understand language? Is the problem execution or formulation?
Identify dysarthria type: Flaccid, spastic, ataxic, hypokinetic, hyperkinetic, or mixed — this localizes the lesion
Perform complete neurological examination: Look for associated findings that point to underlying etiology
Order targeted investigations: Guided by dysarthria type, onset pattern, and examination findings
Consider treatable causes: Myasthenia gravis, Wilson disease, drug-induced, multiple sclerosis — these should not be missed
Assess dysphagia and respiratory function: Critical in all bulbar disease; determines prognosis and urgency
Refer early: Neurology for diagnosis and management; speech therapy for assessment and treatment; other specialists as needed
Address functional impact: Communication, quality of life, mood, and caregiver support
Plan for progression: In degenerative disease, early discussion of prognosis, advance care planning, and augmentative communication

High-Yield Summary: Dysarthria Type to Diagnosis

Dysarthria Type	Localization	Top Diagnoses	Key Distinguishing Features
Flaccid	Lower motor neuron, neuromuscular junction	Myasthenia gravis, bulbar amyotrophic lateral sclerosis, brainstem stroke, Guillain-Barré	Fatigability (myasthenia); fasciculations and atrophy (amyotrophic lateral sclerosis); acute onset (stroke)
Spastic	Bilateral upper motor neuron	Bilateral stroke, primary lateral sclerosis, cerebral palsy	Hyperreflexia, spasticity, pseudobulbar affect
Ataxic	Cerebellum	Multiple sclerosis, spinocerebellar ataxia, cerebellar stroke, alcohol	Gait ataxia, nystagmus, intention tremor, dysdiadochokinesia
Hypokinetic	Basal ganglia (dopaminergic)	Parkinson disease, progressive supranuclear palsy, multiple system atrophy	Rest tremor, rigidity, bradykinesia (Parkinson); vertical gaze palsy, falls (progressive supranuclear palsy)
Hyperkinetic	Basal ganglia (various)	Huntington disease, dystonia, tardive dyskinesia	Chorea, family history (Huntington); sustained postures (dystonia); antipsychotic exposure (tardive)
Mixed	Multiple systems	Amyotrophic lateral sclerosis (flaccid-spastic), multiple sclerosis, Wilson disease	Upper and lower motor neuron signs (amyotrophic lateral sclerosis); young onset (Wilson disease)